These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12356209)

  • 1. Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone.
    Hoogervorst EL; Polman CH; Barkhof F
    Mult Scler; 2002 Oct; 8(5):415-9. PubMed ID: 12356209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
    Then Bergh F; Kümpfel T; Schumann E; Held U; Schwan M; Blazevic M; Wismüller A; Holsboer F; Yassouridis A; Uhr M; Weber F; Daumer M; Trenkwalder C; Auer DP
    BMC Neurol; 2006 May; 6():19. PubMed ID: 16719908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.
    Zivadinov R; Rudick RA; De Masi R; Nasuelli D; Ukmar M; Pozzi-Mucelli RS; Grop A; Cazzato G; Zorzon M
    Neurology; 2001 Oct; 57(7):1239-47. PubMed ID: 11591843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS.
    Martinelli V; Rocca MA; Annovazzi P; Pulizzi A; Rodegher M; Martinelli Boneschi F; Scotti R; Falini A; Sormani MP; Comi G; Filippi M
    Neurology; 2009 Dec; 73(22):1842-8. PubMed ID: 19949030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications.
    Fox RJ; Fisher E; Tkach J; Lee JC; Cohen JA; Rudick RA
    Mult Scler; 2005 Apr; 11(2):140-5. PubMed ID: 15794385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of methylprednisolone on emotional functioning of patients with multiple sclerosis].
    Kułakowska A; Drozdowski W; Halicka D; Kochanowicz J; Braszko JJ
    Pol Merkur Lekarski; 2002 Sep; 13(75):200-3. PubMed ID: 12474570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term effects of methylprednisolone on cerebral volume in multiple sclerosis relapses.
    Chapman C; Tubridy N; Cook MJ; Mitchell PJ; MacGregor LR; Lovelock C; Litewka L; Sedal L; Kilpatrick TJ; Butzkueven H
    J Clin Neurosci; 2006 Jul; 13(6):636-8. PubMed ID: 16790352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis.
    Zivadinov R; Zorzon M; De Masi R; Nasuelli D; Cazzato G
    J Neurol Sci; 2008 Apr; 267(1-2):28-35. PubMed ID: 17945260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.
    Rudick RA; Fisher E; Lee JC; Duda JT; Simon J
    Mult Scler; 2000 Dec; 6(6):365-72. PubMed ID: 11212130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis.
    Nos C; Sastre-Garriga J; Borràs C; Río J; Tintoré M; Montalban X
    Mult Scler; 2004 Aug; 10(4):413-6. PubMed ID: 15327039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
    Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
    Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes.
    Di Gregorio M; Gaetani L; Eusebi P; Floridi P; Picchioni A; Rosi G; Mancini A; Floridi C; Baschieri F; Gentili L; Sarchielli P; Calabresi P; Di Filippo M
    J Neurol; 2018 Mar; 265(3):522-529. PubMed ID: 29327284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atorvastatin calcium in combination with methylprednisolone for the treatment of multiple sclerosis relapse.
    Li XL; Zhang ZC; Zhang B; Jiang H; Yu CM; Zhang WJ; Yan X; Wang MX
    Int Immunopharmacol; 2014 Dec; 23(2):546-9. PubMed ID: 25448497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
    Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.
    Le Page E; Veillard D; Laplaud DA; Hamonic S; Wardi R; Lebrun C; Zagnoli F; Wiertlewski S; Deburghgraeve V; Coustans M; Edan G; ;
    Lancet; 2015 Sep; 386(9997):974-81. PubMed ID: 26135706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in multiple sclerosis.
    Sharrack B; Hughes RA; Morris RW; Soudain S; Wade-Jones O; Barnes D; Brown P; Britton T; Francis DA; Perkin GD; Rudge P; Swash M; Katifi HA; Farmer S; Frankel JP
    J Neurol Sci; 2000 Feb; 173(1):73-7. PubMed ID: 10675582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal associations between brain structural changes and fatigue in early MS.
    Nourbakhsh B; Azevedo C; Nunan-Saah J; Maghzi AH; Spain R; Pelletier D; Waubant E
    Mult Scler Relat Disord; 2016 Jan; 5():29-33. PubMed ID: 26856940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain atrophy in multiple sclerosis: impact of lesions and of damage of whole brain tissue.
    Kalkers NF; Vrenken H; Uitdehaag BM; Polman CH; Barkhof F
    Mult Scler; 2002 Oct; 8(5):410-4. PubMed ID: 12356208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.